AIII. Furthermore, prophylaxis with systemic azoles should not be initiated during pregnancy. Prophylactic systemic sialogogues: Pilocarpine (Salagen®) - Consult pt’s physician before prescribing. Alternatively, oral sialogogues include sugarless gum and sugarless hard lozenges. Salivary stimulants: artificial saliva substitutes. Oral and/or systemic sialogogues are used to augment saliva production in patients with HIV infection and other conditions characterized by reduced saliva production (HIV/AIDS, AIDS, diabetes mellitus, Sjögren’s syndrome). Oral sialogogue regimens include a high fluid diet and frequent sips of water, 5 mL every 2 hours and before meals, expectorate cotton swab to ulcers bid, or fluocinonide 0.05% ointment apply to affected areas after meals and at bedtime as needed. Press medication onto affected area and apply small amount on a cotton swab to affected areas. Note: topical corticosteroids are not commercially available but can be compounded. This pocket resource contains photographs and agents for oral manifestations of HIV disease including: antifungal, antiviral, topical, antibacterial, and other treatments. References:


The information contained in this publication is intended for medical professionals and healthcare providers and does not replace nor represent the comprehensive nature of the published guidelines. Recognizing the rapid changes that occur in this field, clinicians are encouraged to consult local or state sources or materials within the literature for the most up-to-date information to assist with individual treatment decisions. For more information and updates, please subscribe to the FDA's listserv at www.fda.gov/Safety/MedWatch/ForProfessionals/Default.htm to help increase pt safety. HowToReport/default.htm) to help increase pt safety. HowToReport/default.htm) to help increase pt safety. HowToReport/default.htm) to help increase pt safety. HowToReport/default.htm) to help increase pt safety. HowToReport/default.htm) to help increase pt safety. HowToReport/default.htm) to help increase pt safety. HowToReport/default.htm) to help increase pt safety. HowToReport/default.htm) to help increase pt safety. HowToReport/default.htm) to help increase pt safety. HowToReport/default.htm) to help increase pt safety. HowToReport/default.htm) to help increase pt safety. HowToReport/default.htm) to help increase pt safety. HowToReport/default.htm) to help increase pt safety. HowToReport/default.htm) to help increase pt safety. HowToReport/default.htm) to help increase pt safety. HowToReport/default.htm) to help increase pt safety. HowToReport/default.htm) to help increase pt safety. HowToReport/default.htm) to help increase pt safety.

Visit www.FCAETC.org/treatment for the most up-to-date version of this resource.

This publication is made possible by AETC grant award H490046000 from the HIV/AIDS Bureau (HAB) of the Health Resources and Services Administration, HHS. The University of South Florida Center for HIV Education and Research operates an AIDS Education and Training (AETC) for the Florida/Caribbean AETC. The Florida/Caribbean AETC is supported through a cooperative agreement from the U.S. Department of Health and Human Services (HHS). The University of South Florida Center for HIV Education and Research is responsible for the overall management of the AETC. The Florida/Caribbean AETC is supported through a cooperative agreement from the U.S. Department of Health and Human Services (HHS). The University of South Florida Center for HIV Education and Research is responsible for the overall management of the AETC. The information presented and consensus of HIV/AIDS specialists within the Florida/Caribbean AETC and does not necessarily represent the official views of HRSA/HAB.

HERPES SIMPLEX VIRUS

Note: Severe Mucocutaneous HSV Infections (Refer to primary care or specialty physician) Oralabal Lesions Duration of therapy: 5-10 days

Valacyclovir 1 g bid (BIII), or Foscarnet 80-120 mg/kg/day IV in 2-3 divided doses until improvement

Acyclovir 400 mg po bid (BIII)

Chronic Suppressive Therapy: Indications: For pts with severe recurrences (AI)

Acyclovir 400 mg po bid (AI)

Acyclovir 800 mg po 5 times daily

Topical cidofovir, or Foscarnet 80-120 mg/kg/day IV in 2-3 divided doses until improvement

Acyclovir 400 mg po bid (AI)

Acyclovir 800 mg po 5 times daily

Varicella Zoster Virus (Herpes Zoster, Shingle)

Duration of therapy: 1-2 weeks, longer duration should be considered if recurrences are frequent

Acyclovir 1000 mg po tid (BIII) or Foscarnet 4000 mg po bid (AI)

Valacyclovir or Oralab 500 mg po bid (AI)

Acyclovir 800 mg po 5 times daily

XEROSTOMIA

Consult PDR or pharmacology text for more information regarding indications, contraindications and adverse reactions.
Web-Based Education

The F/C AETC provides web-based education to increase the knowledge and skills of HIV healthcare providers. Programs are provided as both live and on-demand recorded webinars.

For more information, please visit:
www.FCAETC.org/education

HIV Prevention Program

This program provides resources to assist with HIV/AIDS prevention initiatives.

For more information, please visit:
www.USFCenter.org/prevention

FIND US ON THE WEB

www.FCAETC.org
www.facebook.com/FCAETC

© 2014
Developed by Carol Stewart, DDS, MS, University of Florida, College of Dentistry
Produced by the Florida/Caribbean AIDS Education and Training Center